Belite Bio (BLTE)

• Market cap: $5.5B
• 1 day: 1.7%
• 5 days: -2.22%
• 1 month: -11.18%
• 3 months: -18.26%
• 6 months: -9.59%
• Year to date: -13.84%
• 1 year: 111.71%
• 5 years: 1,195.85%
• 10 years: 1,195.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Employees: 41